Replies to post #10345 on GTC Biotherapeutics (fka GTCB)

[quantumdot]

"Actually, I did not render an opinion on the likelihood that the FDA will convene a panel."

Quite right. I should have said ...you are both using the term "strong data" when discussing the pros and cons of an advisory panel for ATryn.